Peptide-based positron emission tomography probes: Current strategies for synthesis and radiolabelling
M Failla, G Floresta, V Abbate - RSC Medicinal Chemistry, 2023 - pubs.rsc.org
In medical imaging, techniques such as magnetic resonance imaging, contrast-enhanced
computerized tomography, and positron emission tomography (PET) are extensively …
computerized tomography, and positron emission tomography (PET) are extensively …
Effective Treatment of SSTR2-Positive Small Cell Lung Cancer Using 211At-Containing Targeted α-Particle Therapy Agent Which Promotes Endogenous Antitumor …
S Qin, Y Yang, J Zhang, Y Yin, W Liu… - Molecular …, 2023 - ACS Publications
Small cell lung cancer (SCLC) is a neuroendocrine tumor with a high degree of malignancy.
Due to limited treatment options, patients with SCLC have a poor prognosis. We have found …
Due to limited treatment options, patients with SCLC have a poor prognosis. We have found …
[HTML][HTML] Terbium radionuclides for theranostic applications in nuclear medicine: from atom to bedside
C Van Laere, M Koole, CM Deroose… - Theranostics, 2024 - ncbi.nlm.nih.gov
Terbium features four clinically interesting radionuclides for application in nuclear medicine:
terbium-149, terbium-152, terbium-155, and terbium-161. Their identical chemical properties …
terbium-149, terbium-152, terbium-155, and terbium-161. Their identical chemical properties …
Optimizing the Safety and Efficacy of Bio-Radiopharmaceuticals for Cancer Therapy
CN Funeh, J Bridoux, T Ertveldt, TWM De Groof… - Pharmaceutics, 2023 - mdpi.com
The precise delivery of cytotoxic radiation to cancer cells through the combination of a
specific targeting vector with a radionuclide for targeted radionuclide therapy (TRT) has …
specific targeting vector with a radionuclide for targeted radionuclide therapy (TRT) has …
Design and synthesis of a new bifunctional chelating agent: Application for Al 18F/177Lu complexation
W Laurène, L Raúl, S Katalin, F Céline, K Gilles… - Journal of Inorganic …, 2023 - Elsevier
Theranostic and personalized medicine are blooming strategies to improve oncologic
patients' health care and facilitate early treatment. While 18 F-radiochemistry for theranostic …
patients' health care and facilitate early treatment. While 18 F-radiochemistry for theranostic …
[HTML][HTML] Targeted radiopharmaceuticals: an underexplored strategy for ovarian cancer
Ovarian cancer is the most common gynecological malignancy worldwide with the highest
mortality. This low survival rate can be attributed to the fact that symptoms arise only at an …
mortality. This low survival rate can be attributed to the fact that symptoms arise only at an …
[HTML][HTML] Direct comparison of [18F] AlF-NOTA-JR11 and [18F] AlF-NOTA-octreotide for PET imaging of neuroendocrine tumors: Antagonist versus agonist
Abstract Background [18 F] AlF-NOTA-octreotide is an 18 F-labeled somatostatin analogue
which is a good clinical alternative for 68 Ga-labeled somatostatin analogues. However …
which is a good clinical alternative for 68 Ga-labeled somatostatin analogues. However …
Pharmacokinetic Positron Emission Tomography Imaging of an Optimized CD38-Targeted 68Ga-Labeled Peptide in Multiple Myeloma: A Pilot Study
Q Yang, L Song, Z Chen, Y Qiu, T Wang… - Bioconjugate …, 2024 - ACS Publications
Multiple myeloma (MM) is an incurable disease characterized by its clinical and prognostic
heterogeneity. Despite conventional chemotherapy and autologous hematopoietic stem cell …
heterogeneity. Despite conventional chemotherapy and autologous hematopoietic stem cell …
Complete remissions of HER2-positive trastuzumab-resistant xenografts using a potent [225Ac] Ac-labeled anti-HER2 antibody-drug radioconjugate
J Pougoue Ketchemen, FN Njotu… - Clinical Cancer …, 2024 - aacrjournals.org
Purpose: There is overwhelming interest to use actinium-225 ([225Ac] Ac) to develop
targeted alpha therapies. Antibody-drug conjugates (ADCs) are highly cytotoxic. Combining …
targeted alpha therapies. Antibody-drug conjugates (ADCs) are highly cytotoxic. Combining …
Effectiveness of [67Cu]Cu-trastuzumab as a theranostic against HER2-positive breast cancer
J Pougoue Ketchemen, FN Njotu, H Babeker… - European Journal of …, 2024 - Springer
Purpose To evaluate the imaging and therapeutic properties (theranostic) of 67Cu-labeled
anti-human epidermal growth factor receptor II (HER2) monoclonal antibody trastuzumab …
anti-human epidermal growth factor receptor II (HER2) monoclonal antibody trastuzumab …